Colorado-based nano-biotechnology company NanoSphere Health Sciences, Inc. has developed an innovative, patented nanoencapsulation delivery, known as the NanoSphere Delivery System™ (NDS). This technology solves the low bioavailability challenge by enabling the efficient delivery of active ingredients into the circulatory system and target receptors in the form of pharmaceuticals, cosmeceuticals, nutraceuticals, phytonutrients, over-the-counter medications, and cannabinoids. Utilization of nanosized particles, which over a patented unified high-energy homogenization process, create a protective lipid membrane around therapeutic agents, rapidly and safely transports them into the bloodstream and cells, thus supporting increased absorption by way of intra-oral, intra-nasal, and transdermal products.

Unlike competing technologies that are based on gold nanoparticles or a polymer matrix as delivery carriers, NanoSphere Health utilizes commercial phospholipids, as they are well accepted by the body, fully natural and biodegradable, materials that enable excellent intracellular penetration and stability. 

NanoSphere Health is the first to conduct pharmacokinetic examination of cannabis nanoparticles, and to an impressive end. The onset time of cannabinoids delivered by the NanoSphere Delivery System™ is just 10 minutes, thereby providing relief in an extremely short period of time.

To review our Clinical Study summary, please click here.